ROIV
Roivant Sciences Ltd.
$29.96
-0.92
(-2.98%)
Mkt Cap
21.55B
Volume
5,026,651
52W Range
10.594-32.793
Sector
Healthcare
Beta
1.14
EPS (TTM)
-0.45
P/E Ratio
-64.12
Revenue (TTM)
8.26M
Rev Growth (5Y)
-19.1%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
$91.42
Undervalued · Strong
67.2% below fair value
AlphaQuality · Grade · Gated
F
Stable Earnings Power
29.8 / 100 pillar composite (overridden)
Company Description
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 8.26M | 29.05M | 32.71M | 31.53M | 55.29M | 23.80M | 67.69M |
| Net Income | (299.77M) | (171.98M) | 4.35B | (1.01B) | (845.26M) | (809.23M) | 1.20B |
| EPS | -0.43 | -0.24 | 5.55 | -1.42 | -1.26 | -1.18 | 1.75 |
| Free Cash Flow | (758.56M) | (844.05M) | (766.65M) | (856.08M) | (695.16M) | (557.94M) | (766.75M) |
| FCF / Share | -1.09 | -1.16 | -0.98 | -1.20 | -1.04 | -0.81 | -1.12 |
| Operating CF | (750.35M) | (839.45M) | (765.27M) | (843.39M) | (677.73M) | (552.14M) | (761.83M) |
| Total Assets | 5.73B | 5.44B | 7.22B | 2.39B | 2.59B | 2.69B | 2.48B |
| Total Debt | 107.44M | 100.17M | 499.75M | 481.40M | 283.89M | 244.98M | 180.88M |
| Cash & Equiv | 1.42B | 2.72B | 6.54B | 1.68B | 2.06B | 2.13B | 2.19B |
| Book Value | 4.53B | 4.69B | 5.97B | 1.16B | 1.66B | 1.90B | 2.03B |
| Return on Equity | -0.07 | -0.04 | 0.73 | -0.87 | -0.51 | -0.43 | 0.59 |
| Metric | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.52M | 2.00M | 1.57M | 2.17M | 7.57M | 9.02M | 4.47M | 7.99M | 28.93M | 15.56M | 3.65M | 21.62M |
| Net Income | 302.99M | (265.89M) | (113.52M) | (223.35M) | (206.47M) | 169.38M | (230.18M) | 95.30M | (151.12M) | 5.10B | (304.33M) | (291.82M) |
| EPS | 0.43 | -0.38 | -0.17 | -0.33 | -0.29 | 0.23 | -0.31 | 0.13 | -0.19 | 6.37 | -0.40 | -0.38 |
| Free Cash Flow | (165.08M) | (191.55M) | (193.51M) | (208.42M) | (173.38M) | (209.08M) | (267.80M) | (193.79M) | (108.81M) | (210.81M) | (196.70M) | (250.34M) |
| FCF / Share | -0.24 | -0.27 | -0.28 | -0.31 | -0.25 | -0.29 | -0.36 | -0.26 | -0.14 | -0.26 | -0.26 | -0.33 |
| Operating CF | (163.82M) | (196.48M) | (185.66M) | (204.38M) | (172.56M) | (207.25M) | (266.81M) | (192.83M) | (108.46M) | (210.45M) | (196.43M) | (249.93M) |
| Total Assets | 5.73B | 5.23B | 5.06B | 5.03B | 5.44B | 5.79B | 6.21B | 6.50B | 7.22B | 7.31B | 2.07B | 2.14B |
| Total Debt | 107.44M | 207.44M | 98.85M | 99.69M | 100.17M | 100.31M | 52.71M | 379.06M | 499.75M | 506.58M | 497.98M | 492.63M |
| Cash & Equiv | 1.42B | 1.48B | 1.24B | 1.24B | 2.72B | 1.99B | 1.96B | 5.68B | 6.54B | 6.67B | 1.41B | 1.44B |
| Book Value | 4.53B | 4.27B | 4.36B | 4.35B | 4.69B | 5.19B | 5.15B | 5.44B | 5.97B | 6.09B | 948.53M | 910.73M |
| Return on Equity | 0.07 | -0.06 | -0.03 | -0.05 | -0.04 | 0.03 | -0.04 | 0.02 | -0.03 | 0.84 | -0.32 | -0.32 |
ROIV News
Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy
Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript
Roivant Sciences Q4 Earnings Call Highlights
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's Why
Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
Roivant Sciences: Moderna Settlement And Brepocitinib Support A Long-Term Buy